145 related articles for article (PubMed ID: 36944564)
1. Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study.
Leung BW; Wan G; Nguyen N; Rashdan H; Zhang S; Chen W; Cohen S; Boland GM; Sullivan RJ; Fadden RM; Kaufman HL; Kwatra SG; LeBoeuf NR; Semenov YR
J Am Acad Dermatol; 2023 Jun; 88(6):1265-1270. PubMed ID: 36944564
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
medRxiv; 2023 Jan; ():. PubMed ID: 36711758
[TBL] [Abstract][Full Text] [Related]
4. Cancer Type and Histology Influence Cutaneous Immunotherapy Toxicities: A Multi-Institutional Cohort Study.
Wan G; Khattab S; Leung BW; Zhang S; Nguyen N; Tran M; Lin C; Chang C; Alexander N; Jairath R; Phillipps J; Tang K; Rajeh A; Zubiri L; Chen ST; Demehri S; Yu KH; Gusev A; Kwatra SG; LeBoeuf NR; Reynolds KL; Semenov YR
Br J Dermatol; 2024 Feb; ():. PubMed ID: 38366637
[TBL] [Abstract][Full Text] [Related]
5. Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy.
Nguyen N; Wan G; Ugwu-Dike P; Alexander NA; Raval N; Zhang S; Jairath R; Phillipps J; Leung B; Roster K; Seo J; Lu C; Tang K; Choi MS; DeSimone MS; Theodosakis N; Amadife M; Cox N; Le TK; Liu F; Chen W; Bai X; Boland G; Liu D; Hurlbert MS; LeBoeuf N; Reynolds KL; Yu KH; Tsao H; Asgari M; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 Jun; 88(6):1308-1316. PubMed ID: 36828138
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Cutaneous and Noncutaneous Immune-Related Adverse Events Among Patients With Advanced Cancer.
Thompson LL; Krasnow NA; Chang MS; Yoon J; Li EB; Polyakov NJ; Molina GE; Said JT; Huang K; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
JAMA Dermatol; 2021 May; 157(5):577-582. PubMed ID: 33760001
[TBL] [Abstract][Full Text] [Related]
7. Incidence and factors associated with cutaneous immune-related adverse events to immune check point inhibitors: An ambispective cohort study.
Luangnara A; Kiratikanon S; Ketpueak T; Suksombooncharoen T; Charoentum C; Chewaskulyong B; Tovanabutra N; Chiewchanvit S; Nochaiwong S; Chuamanochan M
Front Immunol; 2022; 13():965550. PubMed ID: 36341419
[TBL] [Abstract][Full Text] [Related]
8. Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity.
Thompson LL; Li EB; Krasnow NA; Chang MS; Said JT; Molina GE; Polyakov NJ; Yoon J; Dee EC; Huang K; Blum AE; Kuchroo JR; Hinton AN; Reynolds KL; Chen ST
Br J Dermatol; 2021 Sep; 185(3):627-635. PubMed ID: 33733456
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Adverse Events and Cancer Survival Prognosis With Immune Checkpoint Inhibitor Treatment: A Systematic Review and Meta-Analysis.
Du Y; Wu W; Chen M; Dong Z; Wang F
JAMA Dermatol; 2023 Oct; 159(10):1093-1101. PubMed ID: 37672255
[TBL] [Abstract][Full Text] [Related]
10. Pre-Existing Inflammatory Disease Predicts Cutaneous Immunotherapy Toxicity Development: A Multi-Institutional Cohort Study.
Wan G; Nguyen N; Leung BW; Rashdan H; Tang K; Roster K; Collier MR; Ugwu-Dike PO; Raval NS; Alexander NA; Jairath R; Phillipps J; Amadife M; Zhang S; Gusev A; Chen ST; Reynolds KL; LeBoeuf NR; Kwatra SG; Semenov YR
medRxiv; 2023 Aug; ():. PubMed ID: 37693493
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic accuracy of general dermatologists and supportive oncodermatologists for biopsied cutaneous immune-related adverse events.
Thompson LL; Said JT; Li EB; Yoon J; Krasnow NA; Molina GE; Polyakov NJ; Foreman RK; LeBoeuf NR; Chen ST
Support Care Cancer; 2022 Oct; 30(10):7827-7831. PubMed ID: 35804176
[TBL] [Abstract][Full Text] [Related]
12. Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases.
Everett AS; Pavlidakey PG; Contreras CM; De Los Santos JF; Kim JY; McKee SB; Kaufman HL; Conry RM
J Cutan Pathol; 2018 Jan; 45(1):48-53. PubMed ID: 28940544
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis.
Curkovic NB; Bai K; Ye F; Johnson DB
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254829
[TBL] [Abstract][Full Text] [Related]
15. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
16. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
17. Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy.
Duraisamy P; Panicker VV; Jose WM
Dermatol Pract Concept; 2023 Jul; 13(3):. PubMed ID: 37557151
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma.
Andtbacka RH; Agarwala SS; Ollila DW; Hallmeyer S; Milhem M; Amatruda T; Nemunaitis JJ; Harrington KJ; Chen L; Shilkrut M; Ross M; Kaufman HL
Head Neck; 2016 Dec; 38(12):1752-1758. PubMed ID: 27407058
[TBL] [Abstract][Full Text] [Related]
19. Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.
Louie RJ; Perez MC; Jajja MR; Sun J; Collichio F; Delman KA; Lowe M; Sarnaik AA; Zager JS; Ollila DW
J Am Coll Surg; 2019 Apr; 228(4):644-649. PubMed ID: 30690076
[TBL] [Abstract][Full Text] [Related]
20. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
